Validation of dried blood spot sample modifications to two commercially available COVID-19 IgG antibody immunoassays.
Bioanalysis
; 13(1): 13-28, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-977787
ABSTRACT
Aim:
Coronavirus disease 2019 antibody testing often relies on venous blood collection, which is labor-intensive, inconvenient and expensive compared with finger-stick capillary dried blood spot (DBS) collection. The purpose of our work was to determine if two commercially available anti-severe acute respiratory syndrome coronavirus 2 enzyme-linked immunosorbent assays for IgG antibodies against spike S1 subunit and nucleocapsid proteins could be validated for use with DBS. Materials &methods:
Kit supplied reagents were used to extract DBS, and in-house DBS calibrators were included on every run.Results:
Positive/negative concordance between DBS and serum was 100/99.3% for the spike S1 subunit assay and 100/98% for the nucleocapsid assay.Conclusion:
Validation of the DBS Coronavirus disease 2019 IgG antibody assays demonstrated that serum and DBS can produce equivalent results with minimal kit modifications.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Enzyme-Linked Immunosorbent Assay
/
Dried Blood Spot Testing
/
COVID-19 Testing
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Bioanalysis
Year:
2021
Document Type:
Article
Affiliation country:
Bio-2020-0289
Similar
MEDLINE
...
LILACS
LIS